HCW Biologics Inc
HCWB
View Detailed Chart
1.490USD
-0.067-4.30%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
3.91MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-4.30%
5 Days
-14.12%
1 Month
-31.34%
6 Months
-65.90%
Year to Date
-91.65%
1 Year
-90.64%
View Detailed Chart
TradingKey Stock Score of HCW Biologics Inc
Currency: USD Updated: 2025-12-24Key Insights
HCW Biologics Inc's fundamentals are relatively weak, and its growth potential is significant.Its valuation is considered fairly valued, ranking 199/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 35.00.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
HCW Biologics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
35.000
Target Price
+1676.65%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
HCW Biologics Inc Highlights
StrengthsRisks
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.57M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.57M.
Overvalued
The company’s latest PE is -0.11, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 36.93K shares, decreasing 60.26% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.68.
HCW Biologics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
HCW Biologics Inc Info
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Ticker SymbolHCWB
CompanyHCW Biologics Inc
CEOWong (Hing C)
Websitehttps://hcwbiologics.com/
FAQs
What is the current price of HCW Biologics Inc (HCWB)?
The current price of HCW Biologics Inc (HCWB) is 1.490.
What is the symbol of HCW Biologics Inc?
The ticker symbol of HCW Biologics Inc is HCWB.
What is the 52-week high of HCW Biologics Inc?
The 52-week high of HCW Biologics Inc is 41.200.
What is the 52-week low of HCW Biologics Inc?
The 52-week low of HCW Biologics Inc is 1.515.
What is the market capitalization of HCW Biologics Inc?
The market capitalization of HCW Biologics Inc is 3.91M.
What is the net income of HCW Biologics Inc?
The net income of HCW Biologics Inc is -30.02M.
Is HCW Biologics Inc (HCWB) currently rated as Buy, Hold, or Sell?
According to analysts, HCW Biologics Inc (HCWB) has an overall rating of Buy, with a price target of 35.000.
What is the Earnings Per Share (EPS TTM) of HCW Biologics Inc (HCWB)?
The Earnings Per Share (EPS TTM) of HCW Biologics Inc (HCWB) is -13.960.
Related Instruments
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
